JPWO2020081848A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020081848A5
JPWO2020081848A5 JP2021520556A JP2021520556A JPWO2020081848A5 JP WO2020081848 A5 JPWO2020081848 A5 JP WO2020081848A5 JP 2021520556 A JP2021520556 A JP 2021520556A JP 2021520556 A JP2021520556 A JP 2021520556A JP WO2020081848 A5 JPWO2020081848 A5 JP WO2020081848A5
Authority
JP
Japan
Prior art keywords
pyrido
thio
pyrazin
amine
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021520556A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022504936A (ja
JP7449282B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/056786 external-priority patent/WO2020081848A1/en
Publication of JP2022504936A publication Critical patent/JP2022504936A/ja
Publication of JPWO2020081848A5 publication Critical patent/JPWO2020081848A5/ja
Application granted granted Critical
Publication of JP7449282B2 publication Critical patent/JP7449282B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021520556A 2018-10-17 2019-10-17 タンパク質チロシンホスファターゼ阻害薬 Active JP7449282B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862746952P 2018-10-17 2018-10-17
US62/746,952 2018-10-17
US201962916119P 2019-10-16 2019-10-16
US62/916,119 2019-10-16
PCT/US2019/056786 WO2020081848A1 (en) 2018-10-17 2019-10-17 Protein tyrosine phosphatase inhibitors

Publications (3)

Publication Number Publication Date
JP2022504936A JP2022504936A (ja) 2022-01-13
JPWO2020081848A5 true JPWO2020081848A5 (es) 2022-10-07
JP7449282B2 JP7449282B2 (ja) 2024-03-13

Family

ID=68536896

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021520556A Active JP7449282B2 (ja) 2018-10-17 2019-10-17 タンパク質チロシンホスファターゼ阻害薬

Country Status (27)

Country Link
US (1) US20210380582A1 (es)
EP (1) EP3867238B1 (es)
JP (1) JP7449282B2 (es)
KR (1) KR102649419B1 (es)
CN (1) CN114341124B (es)
AU (1) AU2019359885B2 (es)
BR (1) BR112021005733A2 (es)
CA (1) CA3116561C (es)
CL (1) CL2021000972A1 (es)
CO (1) CO2021004966A2 (es)
CR (1) CR20210189A (es)
CU (1) CU20210029A7 (es)
CY (1) CY1126122T1 (es)
DO (1) DOP2021000070A (es)
EC (1) ECSP21027049A (es)
ES (1) ES2947464T3 (es)
HU (1) HUE062404T2 (es)
IL (1) IL282179B1 (es)
MA (1) MA53921A (es)
MX (1) MX2021004410A (es)
NI (1) NI202100027A (es)
PE (1) PE20211465A1 (es)
PH (1) PH12021550674A1 (es)
PL (1) PL3867238T3 (es)
SG (1) SG11202102985YA (es)
WO (1) WO2020081848A1 (es)
ZA (1) ZA202101960B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11529347B2 (en) 2016-09-22 2022-12-20 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of use thereof
WO2018081091A1 (en) 2016-10-24 2018-05-03 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
EP3630770B1 (en) 2017-05-26 2024-08-28 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
WO2019067843A1 (en) 2017-09-29 2019-04-04 Relay Therapeutics, Inc. PYRAZOLO [3,4-B] PYRAZINE DERIVATIVES AS INHIBITORS OF PHOSPHATASE SHP2
TW202003471A (zh) 2018-03-21 2020-01-16 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法
EP3860717A1 (en) 2018-10-03 2021-08-11 Gilead Sciences, Inc. Imidozopyrimidine derivatives
CR20210501A (es) 2019-04-02 2021-11-02 Array Biopharma Inc Inhibidores de la proteína tirosina fosfatasa
AU2020354475A1 (en) 2019-09-24 2022-05-05 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of making and using the same
CN114901662A (zh) 2019-11-08 2022-08-12 锐新医药公司 双环杂芳基化合物及其用途
BR112022025550A2 (pt) 2020-06-18 2023-03-07 Revolution Medicines Inc Métodos para retardar, prevenir e tratar resistência adquirida aos inibidores de ras
CA3187757A1 (en) 2020-09-03 2022-03-24 Ethan AHLER Use of sos1 inhibitors to treat malignancies with shp2 mutations
TW202227460A (zh) 2020-09-15 2022-07-16 美商銳新醫藥公司 Ras抑制劑
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶-1,6(2h,7h)-二酮
JP2024516450A (ja) 2021-05-05 2024-04-15 レボリューション メディシンズ インコーポレイテッド 共有結合性ras阻害剤及びその使用
TW202309053A (zh) 2021-05-05 2023-03-01 美商銳新醫藥公司 Ras抑制劑
CR20230570A (es) 2021-05-05 2024-01-22 Revolution Medicines Inc Inhibidores de ras
CN115960109B (zh) * 2021-05-31 2024-06-25 药雅科技(上海)有限公司 稠环类shp2磷酸酶抑制剂的制备及其应用
TW202244049A (zh) * 2021-05-12 2022-11-16 大陸商藥雅科技(上海)有限公司 Shp2磷酸酶抑制劑的製備及其應用
CN115340561A (zh) * 2021-05-14 2022-11-15 药雅科技(上海)有限公司 Shp2磷酸酶稠环类抑制剂的制备及其应用
WO2022259157A1 (en) 2021-06-09 2022-12-15 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor
TW202317100A (zh) 2021-06-23 2023-05-01 瑞士商諾華公司 包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途
WO2023282702A1 (ko) 2021-07-09 2023-01-12 주식회사 카나프테라퓨틱스 Shp2 억제제 및 이의 용도
CA3224341A1 (en) 2021-09-01 2023-03-09 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
TW202346305A (zh) * 2022-01-05 2023-12-01 美商雷密克斯醫療公司 用於調節剪切之化合物及方法
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
CN114621186A (zh) * 2022-05-12 2022-06-14 上海维申医药有限公司 作为ras信号通路调控剂的杂环化合物
TW202404581A (zh) 2022-05-25 2024-02-01 美商醫肯納腫瘤學公司 Mek抑制劑及其用途
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JPWO2007029847A1 (ja) * 2005-09-07 2009-03-19 萬有製薬株式会社 二環性芳香族置換ピリドン誘導体
WO2011032050A2 (en) * 2009-09-11 2011-03-17 Trius Therapeutics, Inc. Gyrase inhibitors
EP2575462B1 (en) * 2010-05-24 2016-06-22 Intellikine, LLC Heterocyclic compounds and uses thereof
WO2015107493A1 (en) 2014-01-17 2015-07-23 Novartis Ag 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
JP6473457B2 (ja) 2014-01-17 2019-02-20 ノバルティス アーゲー Shp2の活性を阻害するための1−(トリアジン−3−イル/ピリダジン−3−イル)−ピペリジン/ピペラジン誘導体およびその組成物
ES2824576T3 (es) 2015-06-19 2021-05-12 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
ES2741746T3 (es) 2015-06-19 2020-02-12 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
ES2805232T3 (es) 2015-06-19 2021-02-11 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
AU2017274199B2 (en) 2016-05-31 2021-09-23 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of PTPN11
WO2017211303A1 (en) 2016-06-07 2017-12-14 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
KR102457146B1 (ko) 2016-06-14 2022-10-19 노파르티스 아게 Shp2의 활성을 억제하기 위한 화합물 및 조성물
IL311645A (en) 2016-07-12 2024-05-01 Revolution Medicines Inc 2,5-dimethomers of 3-methylpyrazines and 2,5,6-dimethomers of 3-methylpyrazines as allosteric SHP2 inhibitors
US11529347B2 (en) 2016-09-22 2022-12-20 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of use thereof
WO2018081091A1 (en) * 2016-10-24 2018-05-03 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
CA3051054A1 (en) 2017-01-23 2018-07-26 Revolution Medicines, Inc. Pyridine compounds as allosteric shp2 inhibitors
MX2019008695A (es) 2017-01-23 2019-09-11 Revolution Medicines Inc Compuestos biciclicos como inhibidores alostericos de shp2.
US10988466B2 (en) 2017-03-23 2021-04-27 Jacobio Pharmaceuticals Co., Ltd. Heterocyclic derivatives useful as SHP2 inhibitors
JP7356414B2 (ja) 2017-09-07 2023-10-04 レヴォリューション・メディスンズ,インコーポレイテッド がんを治療するためのshp2阻害剤組成物および方法

Similar Documents

Publication Publication Date Title
JPWO2020081848A5 (es)
KR101812357B1 (ko) Cdk4/6의 억제제로서의 피롤로피리미딘 화합물
EP3867238B1 (en) Protein tyrosine phosphatase inhibitors
JP6631616B2 (ja) CDK阻害剤としての2−アミノ−ピリド[2,3−d]ピリミジン−7(8H)−オン誘導体及びその使用
AU2013287176C1 (en) Substituted tricyclic compounds as FGFR inhibitors
RU2020133727A (ru) Ингибиторы shp2 и их применение
JP2015521600A5 (es)
JP2022543689A (ja) Shp2阻害剤
JPWO2019191092A5 (es)
HRP20230120T1 (hr) Inhibitori bcl6
AU2022265682A1 (en) 2-aminobenzothiazole compounds and methods of use thereof
WO2023069959A1 (en) Covalent egfr inhibitors and methods of use thereof
WO2024086809A1 (en) Methods for treating cancer
JPWO2019197842A5 (es)
JPWO2019233941A5 (es)
JPWO2020207991A5 (es)
RU2023134860A (ru) Ингибиторы мутации her2
RU2020142969A (ru) СОЕДИНЕНИЯ ТЕТРАГИДРО-1Н-ПИРАЗИНО[2,1- a]ИЗОИНДОЛИЛХИНОЛИНА ДЛЯ ЛЕЧЕНИЯ АУТОИММУННОГО ЗАБОЛЕВАНИЯ
JPWO2022013136A5 (es)
TW202423440A (zh) Kras g12c突變蛋白的系鏈之雜環抑制劑及其用途
HUE025203T2 (en) CDK4 / 6 inhibitor pyrrolopyrimidine compounds